CASI Pharmaceuticals Inc. Stock
Currently there is a rather positive sentiment for CASI Pharmaceuticals Inc. with 3 Buy predictions and 0 Sell predictions.
With a target price of 3 € there is a hugely positive potential of 88.68% for CASI Pharmaceuticals Inc. compared to the current price of 1.59 €.
Our community identified positive and negative aspects for CASI Pharmaceuticals Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the CASI Pharmaceuticals Inc. stock. On the other hand our users think that "Customer and product portfolio" could be a problem in the future.
Pros and Cons of CASI Pharmaceuticals Inc. in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of CASI Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| CASI Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | 0.330% | 13.033% | 33.509% | 25.076% | 33.836% | 124.560% | 3.920% |
| Evolus Inc | -2.830% | -5.936% | -30.169% | -69.023% | -24.404% | -56.859% | -30.217% |
| Champions Oncology Inc | -3.390% | -5.000% | -3.390% | -46.226% | -1.724% | 54.054% | -39.683% |
Comments
CASI Pharmaceuticals (NASDAQ:CASI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Show more
Ratings data for CASI provided by MarketBeat
CASI Pharmaceuticals, Inc. (NASDAQ: CASI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Show more
Ratings data for CASI provided by MarketBeat
CASI Pharmaceuticals, Inc. (NASDAQ: CASI) had its price target lowered by analysts at HC Wainwright from $6.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CASI provided by MarketBeat